Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Thoughts??

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 13, 2020 7:40pm

168 Views

Post# 31900082

RE:Thoughts??

If there is going to be a buyout, I think a company would wait for the "All Clear" from the FDA and from the European equivalent for Phase 3 to begin.

There are studies underway (Phase 3 enabling) that a buyer will want to see - making the purchase less risky than buying now.

Just my opinion based on your question.

<< Previous

Bullboard Posts

Next >>

Three stocks with strong income statements to buy right now